Loading...
Intel Corp (INTC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently facing negative price momentum, supply constraints, and mixed analyst sentiment. While there are some positive long-term catalysts such as AI-driven growth and foundry progress, the short-term outlook remains uncertain. Given the investor's preference for long-term stability, it is better to hold off on buying until clearer signs of recovery and growth emerge.
The technical indicators suggest a neutral to bearish trend. The MACD is negative and contracting, RSI is neutral at 45.65, and moving averages are converging. The stock is trading below the pivot level of 45.801, with support levels at 43.482 and 42.05, indicating potential downside risk.

Hedge funds have significantly increased their buying activity by 1201.25% over the last quarter.
Analysts like Tigress Financial and Benchmark have highlighted AI-driven growth and foundry progress as long-term positives.
Intel's turnaround efforts and strategic importance as a U.S. semiconductor company provide a long-term growth narrative.
Recent price action shows a -3.03% regular market decline and an additional -1.01% post-market drop, signaling bearish sentiment.
Analysts have mixed views, with many maintaining Neutral ratings and citing supply constraints and structural disadvantages.
Financial performance in Q4 2025 showed declining revenue (-4.11% YoY) and gross margin (-7.69% YoY), though net income improved from a loss perspective.
In Q4 2025, Intel's revenue dropped by -4.11% YoY to $13.67 billion, and gross margin fell to 36.15% (-7.69% YoY). However, net income improved to -$591 million (+369.05% YoY), and EPS increased to -0.12 (+300.00% YoY). The financials indicate some improvement in profitability but highlight ongoing challenges in revenue growth and margins.
Analysts are mixed on Intel. While some firms like Tigress Financial and Benchmark see long-term upside due to AI and foundry progress, others like DA Davidson and UBS remain cautious, citing supply constraints and structural challenges. Price targets range from $41 to $66, with many analysts maintaining Neutral ratings.